Nasdaq suspended Zentek shares; U.S. trading now takes place over the counter.

Zentek Ltd. (TSXV: ZEN) (OTCQX: ZTEKF) announced its decision to not proceed with a share consolidation, leading to the suspension of its Nasdaq listing. The company's shares now trade over the counter (OTCQX: ZTEKF) in the U.S. and continue on the TSX Venture Exchange (ZEN) in Canada. Zentek plans to focus on advancing its core projects and reassess a senior listing in the future.

Original reporting
Published Oct 26, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ZTEKF
Bearish
high confidence
Mentioned
$ZTEKF
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ZTEKFBearishLow
01

Why it matters

The suspension removes the company from Nasdaq, likely reducing analyst coverage and institutional interest.

02

Market read

The listing change is a primary corporate action for a micro‑cap, offering limited trading opportunities.

03

What to watch

Potential future relisting on a major exchange if milestones are met.

Relevance 5/10Novelty 6/10Timing: post-event, after suspension effective Sep 2, 2026

Background

Zentek Ltd. is a Canadian IP commercialization firm focused on graphene-enabled materials.

Company-level read

Ticker impact

$ZTEKFBearishHigh confidence
Context

Zentek's Nasdaq listing was suspended and shares moved to OTCQX trading after the company declined a share consolidation.

Expected impact

downward pressure as investors reassess valuation on the less liquid OTC market

Evidence & confidence

Listing suspension is a material corporate action; OTC trading typically trades at a discount to primary exchange prices.

Market effects

Minimal impact on the broader materials/clean tech sector.

Limited to Canadian and U.S. OTC investors.

Low

Counterpoint

If the company successfully executes its growth projects, the OTC discount could narrow.

Key entities

  • Mohammed (Moe) Jiwan

    Chief Executive Officer of Zentek, quoted on the decision.

Related articles

$BABAMed

Alibaba Is Spinning Off Its Nvidia Rival in a Hong Kong IPO

Alibaba (BABA) announced plans to spin off its AI chip unit, T-Head, via a Hong Kong IPO. The company's stock has declined 30.1% year-to-date. T-Head's valuation is estimated between $25B and $86B, with regulatory approvals pending. Alibaba's AI investment is over $53B, with negative free cash flow. T-Head competes with Nvidia, Huawei, and Baidu's Kunlunxin in China's AI market.

$PFEMed

Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset

Pfizer secured $1.5B in funding from Blackstone Life Sciences to support obesity drug berobenatide, acquired via Metsera. Funding covers development through 2028, with Pfizer retaining ownership. Analysts note the deal helps offset near-term development costs amid upcoming patent expirations, including Eliquis in 2028. Blackstone previously funded Merck's TROP2 antibody-drug conjugate.